<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04614103</url>
  </required_header>
  <id_info>
    <org_study_id>IOV-LUN-202</org_study_id>
    <secondary_id>2020-003629-45</secondary_id>
    <nct_id>NCT04614103</nct_id>
  </id_info>
  <brief_title>Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer</brief_title>
  <official_title>A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients With Metastatic Non-Small-Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Iovance Biotherapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Iovance Biotherapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study&#xD;
      evaluating LN-145 in patients with metastatic NSCLC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      LN-145 is a ready-to-infuse, autologous TIL therapy that utilizes an autologous TIL&#xD;
      manufacturing process, as originally developed by the NCI and further optimized by Iovance&#xD;
      for the treatment of patients with metastatic NSCLC. The cell transfer therapy used in this&#xD;
      study involves patients receiving an NMA lymphocyte depleting preparative regimen, followed&#xD;
      by infusion of autologous TIL, then finally followed by the administration of IL-2.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 7, 2021</start_date>
  <completion_date type="Anticipated">December 2026</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>Up to 60 months</time_frame>
    <description>To evaluate the efficacy of LN-145 in patients with metastatic NSCLC without an actionable driver mutation who have disease progression on or following a single line of approved systemic therapy consisting of combined immune checkpoint inhibitor(s) (CPI[s]) + chemotherapy ± bevacizumab, as determined by objective response rate (ORR), using the RECIST v1.1, as assessed by the Independent Review Committee (IRC) (Cohorts 1 and 2) or by the Investigator (Cohorts 3 and 4)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>Up to 60 months</time_frame>
    <description>To evaluate efficacy parameters such as Objective Response Rate (ORR) per RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Response Rate</measure>
    <time_frame>Up to 60 months</time_frame>
    <description>To evaluate efficacy parameters such as Complete Response Rate (CRR) per RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>Up to 60 months</time_frame>
    <description>To evaluate efficacy parameters such as Duration of Response (DOR) rate per RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate</measure>
    <time_frame>Up to 60 months</time_frame>
    <description>To evaluate efficacy parameters such as Disease Control Rate (DCR) per RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival</measure>
    <time_frame>Up to 60 months</time_frame>
    <description>To evaluate efficacy parameters such as Progression-Free Survival (PFS) per RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to 60 months</time_frame>
    <description>To evaluate efficacy parameters such as Overall Survival (OS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Up to 60 months</time_frame>
    <description>To characterize the safety profile of LN-145 in NSCLC patients, as measured by the incidence of Grade ≥ 3 treatment-emergent adverse events (TEAEs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Core Biopsies</measure>
    <time_frame>Up to 60 months</time_frame>
    <description>For Cohort 3 only: To evaluate the efficiency of generating LN-145 from tumor core biopsies; Percentage successful TIL products generated from core biopsies</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">95</enrollment>
  <condition>Metastatic Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients whose tumors did not express programmed cell death-ligand 1 (PD-L1) (tumor proportion score [TPS] &lt; 1%) prior to their CPI treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients whose tumors expressed PD-L1 (TPS ≥ 1%) prior to their CPI treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients whose tumors do not express PD-L1 (TPS &lt; 1%) prior to their CPI treatment and who are unable to safely undergo a surgical harvest for TIL generation due to at least one of the following:&#xD;
Unacceptable surgical risk&#xD;
Surgically approachable lesion is required for Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 assessment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who have been previously treated with LN-145 in Cohort 1, 2, or 3 of this study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>LN-145</intervention_name>
    <description>A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After NMA lymphodepletion, patients are infused with their autologous TIL (LN-145) followed by IL-2 administration.</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <other_name>TIL, Autologous Tumor Infiltrating Lymphocytes</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>LN-145</intervention_name>
    <description>A tumor sample is harvested via core biopsy from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After NMA lymphodepletion, patients are infused with their autologous TIL (LN-145) followed by IL-2 administration.</description>
    <arm_group_label>Cohort 3</arm_group_label>
    <other_name>TIL, Autologous Tumor Infiltrating Lymphocytes</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed histologic diagnosis of Non-Small-Cell Lung Carcinoma confirmation.&#xD;
&#xD;
          -  Have received a single line of systemic therapy that included CPI and chemotherapy&#xD;
             with documented radiographic disease progression on or following this single line of&#xD;
             systemic therapy.&#xD;
&#xD;
          -  LVEF &gt; 45%, NYHA Class 1; cardiac stress test required&#xD;
&#xD;
          -  FEV1&gt;50% or FEV1/FVC&gt;0.7 (6 min walk test if unable to perform or unreliable&#xD;
             spirometry).&#xD;
&#xD;
          -  At least 1 resectable lesion.&#xD;
&#xD;
          -  Previously irradiated lesion must have radiographic progression prior to harvest.&#xD;
&#xD;
          -  Must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1,&#xD;
             and an estimated life expectancy of ≥ 6 months&#xD;
&#xD;
          -  Patients of childbearing potential or those with partners of childbearing potential&#xD;
             must be willing to practice an approved method of highly effective birth control&#xD;
             during treatment and for 12 months after receiving all protocol-related therapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have known oncogene driver mutations (eg, EGFR, ALK, ROS) which are&#xD;
             sensitive to targeted therapies.&#xD;
&#xD;
          -  Patients who have symptomatic and/or untreated brain metastases.&#xD;
&#xD;
          -  Patients who have organ allograft or prior cell transfer within the past 20 years.&#xD;
&#xD;
          -  Patients who are on systemic steroid therapy ≥ 10 mg/day of prednisone or other&#xD;
             steroid equivalent. Patients receiving steroids as replacement therapy for&#xD;
             adrenocortical insufficiency at ≤ 10 mg/day of prednisone or other steroid equivalent&#xD;
             may be eligible.&#xD;
&#xD;
          -  Patients who have any form of primary immunodeficiency&#xD;
&#xD;
          -  Patients who have received a live or attenuated vaccination within 28 days prior to&#xD;
             the start of treatment&#xD;
&#xD;
          -  Patients who have had another primary malignancy within the previous 3 years&#xD;
&#xD;
          -  Participation in another interventional clinical study within 21 days of the&#xD;
             initiation of treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Iovance Biotherapeutics Study Team</last_name>
    <role>Study Director</role>
    <affiliation>Iovance Biotherapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Iovance Biotherapeutics Study Team</last_name>
    <phone>866-565-4410</phone>
    <email>Clinical.Inquiries@iovance.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UC San Diego Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Christiana Care Health System</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>H Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cooper</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <zip>08103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novant Health - Charlotte</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novant Health - Winston-Salem</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Avera Medical Group Cancer Institute</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Baptist Cancer Center</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38120</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Baylor Charles A. Sammons Cancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Universite de Montreal (CHUM)</name>
      <address>
        <city>Montréal</city>
        <zip>QC H2X 3E4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 21, 2020</study_first_submitted>
  <study_first_submitted_qc>October 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 3, 2020</study_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>LN-145</keyword>
  <keyword>Cell Therapy</keyword>
  <keyword>Autologous Adoptive Cell Therapy</keyword>
  <keyword>Cellular Immuno-therapy</keyword>
  <keyword>Tumor Infiltrating Lymphocytes</keyword>
  <keyword>TIL</keyword>
  <keyword>IL-2</keyword>
  <keyword>Non Small Cell Lung Cancer</keyword>
  <keyword>NSCLC</keyword>
  <keyword>Second line Lung Cancer</keyword>
  <keyword>Bronchial Neoplasms</keyword>
  <keyword>Carcinoma</keyword>
  <keyword>Lung Disease</keyword>
  <keyword>Metastatic Lung Cancer</keyword>
  <keyword>Metastatic Non Small Cell Lung Cancer</keyword>
  <keyword>Lung Carcinoma</keyword>
  <keyword>LN145</keyword>
  <keyword>PD-L1</keyword>
  <keyword>Stage IV Cancer</keyword>
  <keyword>Stage IV Lung Cancer</keyword>
  <keyword>Stage IV Non-Small Cell Lung Cancer</keyword>
  <keyword>Stage IV NSCLC</keyword>
  <keyword>Systemic Therapy</keyword>
  <keyword>2nd line therapy</keyword>
  <keyword>Second line therapy</keyword>
  <keyword>CPI</keyword>
  <keyword>Check point inhibitor</keyword>
  <keyword>Metastatic NSCLC</keyword>
  <keyword>NSCLC Recurrent</keyword>
  <keyword>Recurrent Lung Cancer</keyword>
  <keyword>Recurrent Lung Carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

